載入...
Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
BACKGROUND: Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persisted when analysing a longer time period after li...
Na minha lista:
| 發表在: | BMC Ophthalmol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5715627/ https://ncbi.nlm.nih.gov/pubmed/29202760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-017-0617-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|